Dasatinib News and Research

RSS
Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.
Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers

Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers

Therapeutic effect of imatinib improved with addition of chloroquine

Therapeutic effect of imatinib improved with addition of chloroquine

Data suggesting that omacetaxine can eradicate leukemic stem cells may offer a breakthrough for CML

Data suggesting that omacetaxine can eradicate leukemic stem cells may offer a breakthrough for CML

When less is more: Brief inhibition of cancer target is effective and less toxic

When less is more: Brief inhibition of cancer target is effective and less toxic

Researcher develops method for early detection of leukemia relapse

Researcher develops method for early detection of leukemia relapse

Bosutinib safe, effective for chronic myelogenous leukemia

Bosutinib safe, effective for chronic myelogenous leukemia

Data confirm Dasatinib's effectiveness in resistant chronic myelogenous leukemia

Data confirm Dasatinib's effectiveness in resistant chronic myelogenous leukemia

New role for miRNA in leukemia discovered

New role for miRNA in leukemia discovered

Nilotinib and Dasatinib show promise as therapy for chronic myelogenous leukemia

Nilotinib and Dasatinib show promise as therapy for chronic myelogenous leukemia

Fingolimod shows promise in 2 lethal leukemias

Fingolimod shows promise in 2 lethal leukemias

Combination of drugs might decrease the chance of chronic myeloid leukemia returning

Combination of drugs might decrease the chance of chronic myeloid leukemia returning

Dasatinib shows promise as first treatment for chronic myelogenous leukemia

Dasatinib shows promise as first treatment for chronic myelogenous leukemia

FDA grants accelerated approval for Sprycel (dasatinib)

FDA grants accelerated approval for Sprycel (dasatinib)

New leukemia drug gives renewed hope to those battling drug resistance to the disease

New leukemia drug gives renewed hope to those battling drug resistance to the disease

Dasatinib offers new options for leukemia patients

Dasatinib offers new options for leukemia patients

Dasatinib provides significant benefit in chronic myeloid leukemia patients resistant to Gleevec

Dasatinib provides significant benefit in chronic myeloid leukemia patients resistant to Gleevec